CLN Share Price Performance
zł20.60
-3.50 (-14.52%)
50.0% undervalued intrinsic discount
zł41.18
Fair Value
Price zł20.60
ak2 zł41.18
Fair Valuezł41.18
Share Pricen/a
Celon Pharma S.A. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 8 Fair Values set on narratives written by author
CLN Community Narratives
AK
Fair Value
·Fair Value zł41.18 50.0% undervalued intrinsic discount
Celon Pharma's Revenue Set to Soar with 33% Growth in Five Years
1users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Celon Pharma's Revenue Set to Soar with 33% Growth in Five Years
Celon Pharma is betting on two big moves: building a Europe-based supply hub for a fast-growing weight-loss drug class and pushing key mental health programs into late-stage testing. The upside comes with long timelines and trial risk, but success could reshape the company beyond its current generics business.Read more
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AK
Celon Pharma's Revenue Set to Soar with 33% Growth in Five Years
Fair Value: zł41.18 50.0% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Celon Pharma S.A. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Sep 16, 2026
- 2.01
- 74.32%
- 42.58%
- 2.6%
About CLN
- Founded
- 2002
- Employees
- 564
- CEO
- WebsiteView website
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. Celon Pharma S.A. was founded in 2002 and is based in Lomianki, Poland. The company operates as a subsidiary of Glatton Sp. z o.o.
